Current Hepatitis Reports

, Volume 11, Issue 2, pp 102–110 | Cite as

Management of Patients with Chronic Hepatitis B Before and After Liver Transplantation: An Update

  • Andres F. Carrion
  • Paul Martin
  • Christopher O’Brien
Hepatitis B: Therapeutics (P Martin, Section Editor)

Abstract

The use of newer and more potent antiviral agents against hepatitis B virus (HBV) results in greater viral suppression; however, liver transplantation is still required for complications of HBV infection. Post-transplant outcomes for HBV-related disorders are currently comparable to or slightly better than for other indications for liver transplantation in adults in the United States. In the absence of prophylactic antiviral therapy, recurrent HBV infection occurs invariably in patients with detectable serum HBV-deoxyribonucleic acid (DNA) at the time of transplantation, leading to poorer outcomes with severe graft injury, reduced patient and allograft survival. Therefore, anti-HBV therapy is indicated in all patients with detectable serum HBV-DNA pre-transplantation and prophylactic therapy to prevent recurrent HBV infection is standard-of-care. This review summarizes available evidence for the use of different antiviral agents before liver transplantation, the effectiveness of prophylactic agents in preventing recurrent HBV infection post-liver transplantation, and the efficacy of several regimens for treating recurrent HBV infection post-liver transplantation.

Keywords

Hepatitis B Cirrhosis Liver transplantation 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ocama P, Opio CK, Lee WM. Hepatitis B virus infection: current status. Am J Med. 2005;118:1413.PubMedCrossRefGoogle Scholar
  2. 2.
    Lavanchy D. Hepatitis B Virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.PubMedCrossRefGoogle Scholar
  3. 3.
    Centers for disease control and prevention: hepatitis B FAQs for health professionals. Available at: http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#- Accessed October 2011.
  4. 4.
    Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat. 2006;13:787.PubMedCrossRefGoogle Scholar
  5. 5.
    Wasley A, Miller JT, Finelli L, et al. Surveillance for acute viral hepatitis-United States, 2005. MMWR Surveill Summ. 2007;56:1–24.PubMedGoogle Scholar
  6. 6.
    Centers for disease control and prevention: viral hepatitis statistics & surveillance. Available at: http://www.cdc.gov/hepatitis/Statistics/2009Surveillance/Table3.1.htm Accessed November 2011.
  7. 7.
    Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011.PubMedCrossRefGoogle Scholar
  8. 8.
    Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–55.PubMedCrossRefGoogle Scholar
  10. 10.
    •• Kim WR, Terrault NA, Pedersen RA et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680–6. Data from UNOS show a steady decline in the number of patients with chronic HBV infection listed for liver transplantation (overall); however, the number of patients with HBV infection listed for HCC continues to rise. These trends suggest that widespread use of potent antiviral agents for HBV has contributed to decrease the incidence of decompensated liver disease but not that of HCC. PubMedCrossRefGoogle Scholar
  11. 11.
    • Han SH, Reddy KR, Keeffe EB, et al. Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clin Transplant. 2011;25:E152–62. In the current era of effective antiviral therapy against HBV, HCC is the most indication for liver transplantation in patients with chronic HBV infection. PubMedCrossRefGoogle Scholar
  12. 12.
    Kim WR, Poterucha JJ, Kremers WK, et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl. 2004;10:968–74.PubMedCrossRefGoogle Scholar
  13. 13.
    Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Harrison RF, Davies MH, Goldin RD, et al. Recurrent hepatitis B in liver allografts: a distinctive form of rapidly developing cirrhosis. Histopathology. 1993;23:21–8.PubMedCrossRefGoogle Scholar
  15. 15.
    O’Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992;14:104–11.PubMedCrossRefGoogle Scholar
  16. 16.
    Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl. 2005;11:402–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology. 2003;38:86–95.PubMedCrossRefGoogle Scholar
  18. 18.
    Maina AM, Ciccorossi P, Oliveri F, et al. Diagnosis and monitoring of hepatitis virus infection in liver transplant patients. Transplant Proc. 2003;35:1025–7.PubMedCrossRefGoogle Scholar
  19. 19.
    EASL. Clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.CrossRefGoogle Scholar
  20. 20.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:1–36.Google Scholar
  21. 21.
    Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for pre- and post-liver transplantation patients with lamivudine-resistant hepatitis B. Liver Transpl. 2007;13:349–60.PubMedCrossRefGoogle Scholar
  22. 22.
    Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000;31:207–10.PubMedCrossRefGoogle Scholar
  23. 23.
    Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002;123:719–27.PubMedCrossRefGoogle Scholar
  24. 24.
    Tillmann H, Bock TC, Locarnini SA, et al. Risk factors for selection of YMDD mutants, their consequences in liver transplant recipients, ranging from sudden onset of liver failure to no disease. Hepatology. 2000;32:376A.Google Scholar
  25. 25.
    Hepsera [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2006.Google Scholar
  26. 26.
    Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44:283–90.PubMedCrossRefGoogle Scholar
  27. 27.
    Snow A, Thibault V, Qi X, et al. Combination of adefovir (ADV) and lamivudine (LAM) prevented emergence of adefovir resistance mutations in chronic hepatitis B patients with lamivudine-resistant HBV. Gastroenterology. 2005;128:M945.Google Scholar
  28. 28.
    Tan J, Lok AS. Antiviral therapy for pre- and post-liver transplantation patient with hepatitis B. Liver Transpl. 2007;13:323–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Fontana RJ. Entecavir in decompensated HBV cirrhosis: the future is looking brighter. J Hepatol. 2010;52:147–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analysis. Gastroenterology. 2010;139:1218–29.PubMedCrossRefGoogle Scholar
  31. 31.
    •• Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010;52:176–82. Entecavir is highly effective in suppressing HBV in patients with compensated and decompensated cirrhosis (81.3% and 92.7% viral suppression rates, respectively after 12 months of therapy with 0.5 mg orally, daily). PubMedCrossRefGoogle Scholar
  32. 32.
    Liaw YF, Sheen IS, Lee CM, et al. Tenofovir Disoproxil Fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62–72.PubMedCrossRefGoogle Scholar
  33. 33.
    Singal AK, Fontana RJ. A systematic review of oral antiviral agents in decompensated hepatitis B virus cirrhosis. Hepatology. 2010;52:506A.CrossRefGoogle Scholar
  34. 34.
    Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009;50:2001–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Marzano A, Marengo A, Marietti M, et al. Lactic acidosis during entecavir treatment in decompensated hepatitis B virus-related cirrhosis. Dig Liv Dis. 2011;43:1027–8.CrossRefGoogle Scholar
  36. 36.
    Fortgang IS, Belitsos PC, Chaisson RE, et al. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol. 1995;90:1433–6.PubMedGoogle Scholar
  37. 37.
    Cohen SM, Levy RM, Jovanovich JF, et al. Use of combination oral medications to treat reactivation of hepatitis B. J Clin Gastroenterol. 2009;43:1008–10.PubMedCrossRefGoogle Scholar
  38. 38.
    Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol. 2008;22:335–53.PubMedCrossRefGoogle Scholar
  39. 39.
    Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS. 2007;21:2455–64.CrossRefGoogle Scholar
  40. 40.
    Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect. 2002;78:58–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49:S185–95.PubMedCrossRefGoogle Scholar
  42. 42.
    Lam YF, Yuen MF, Seto WK, et al. Current antiviral therapy of chronic hepatitis B: efficacy and safety. Curr Hepat Rep. 2011;10:235–43.PubMedCrossRefGoogle Scholar
  43. 43.
    Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology. 2006;44:1110–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: possible role of mitochondrial depletion. Hum Pathol. 2001;32:734–40.PubMedCrossRefGoogle Scholar
  45. 45.
    Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78:1171–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Bonjoch A, Figueras M, Estany C, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010;24:2827–33.PubMedCrossRefGoogle Scholar
  47. 47.
    Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132–43.PubMedCrossRefGoogle Scholar
  48. 48.
    Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and American perspective. Liver Transplant. 2005;11:716–32.CrossRefGoogle Scholar
  49. 49.
    Jiang L, Yan LN. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol. 2011;16:2468–75.CrossRefGoogle Scholar
  50. 50.
    Samuel D, Muller R, Graeme A, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology. 1998;27:213–22.PubMedCrossRefGoogle Scholar
  52. 52.
    Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl. 2008;14:S15–22.PubMedCrossRefGoogle Scholar
  53. 53.
    McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation. 1996;61:1358–64.PubMedCrossRefGoogle Scholar
  54. 54.
    •• Katz LH, Paul M, Guy DG, et al. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and metaanalysis. Transpl Infect Dis. 2010;12:292–308. Data from this metaanalysis of 22 studies show that post-transplant prophylaxis against HBV with combination HBIG and lamivudine is superior to either agent alone and results in improved survival compared to HIBG alone.PubMedCrossRefGoogle Scholar
  55. 55.
    Katz LH, Tur-Kaspa R, Guy DG, et al. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. Chochrane Database Syst Rev. 2010;7:CD006005.Google Scholar
  56. 56.
    Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001;33:424–32.PubMedCrossRefGoogle Scholar
  57. 57.
    Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–22.PubMedCrossRefGoogle Scholar
  58. 58.
    Markowitz JS, Martin P, Conrad A, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998;28:585–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000;6:741–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol. 2008;6:696–700.PubMedCrossRefGoogle Scholar
  61. 61.
    Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int. 2009;22:387–94.PubMedCrossRefGoogle Scholar
  62. 62.
    Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007;132:931–7.PubMedCrossRefGoogle Scholar
  63. 63.
    • Yahyazadeh A, Beckebaum S, Cicinnati V, et al. Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra®) in liver transplantation: an open, prospective, single-arm phase III study. Transpl Int. 2011;24:441–50. In this phase III study, self-injection of a novel subcutaneous formulation of HBIG (Zutectra®) provided therapeutic levels of anti-HBs in post-liver transplantation patients. Self-injection of this agent may result in significant reductions of costs associated with intravenous or intramuscular HBIG. PubMedCrossRefGoogle Scholar
  64. 64.
    • Cholongitas E, Goulis J, Akriviadis E, et al. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl. 2011;17:1176–90. Combination therapy with adefovir and HBIG resulted in lower recurrence rates of HBV post-transplant compared to lamivudine plus HBIG. CrossRefGoogle Scholar
  65. 65.
    Angus PW, Patterson SJ, Strasser SI, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology. 2008;48:1460–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Xi ZF, Qiang XIA, Xhang JJ, et al. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis. 2009;10:321–7.PubMedCrossRefGoogle Scholar
  67. 67.
    •• Cai CJ, Lu MQ, Chen YH, et al. Clinical study on prevention of HBV re-infection by entecavir after liver transplantation. Clin Transplant. 2011; [Epub ahead of print]. Data from this case control study suggest that entecavir is effective in preventing recurrent HBV infection post-liver transplantation. Google Scholar
  68. 68.
    Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology. 2011;141:1212–9.PubMedCrossRefGoogle Scholar
  69. 69.
    •• Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004;48:3498–507. Entecavir monoprophylaxis post-liver transplantation effectively suppresses HBV-DNA in 91% of patients after 2 years of follow up. PubMedCrossRefGoogle Scholar
  70. 70.
    Kwak MS, Choi JW, Lee JS, et al. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir. J Viral Hepat. 2011;18:e432–8.PubMedCrossRefGoogle Scholar
  71. 71.
    •• Saab S, Desai S, Tsaoi D, et al. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant. 2011;11:511–7. Data from this retrospective study suggest that prophylactic therapy with tenofovir plus lamivudine is effective in preventing HBV recurrence post-liver transplantation. PubMedCrossRefGoogle Scholar
  72. 72.
    •• Teperman L, Spivey J, Poordad F, et al. Interim 48 week results of a randomized trial of emtricitabine/tenofovir DF plus/minus HBIG withdrawal in post-orthotopic liver transplant recipients for chronic hepatitis B. J Hepatol. 2011;54:S234. Combination therapy with tenofovir plus emtricitabine resulted in 0% HBV recurrence in 37 post-liver transplant patients. CrossRefGoogle Scholar
  73. 73.
    Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–88.PubMedCrossRefGoogle Scholar
  74. 74.
    Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–95.PubMedCrossRefGoogle Scholar
  75. 75.
    Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology. 1999;29:1581–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Rayes N, Seehofer D, Hopf U, et al. Comparison of famciclovir and lamivudine in the long-term treatment of Hepatitis B infection after liver transplantation. Transplantation. 2001;71:96–101.PubMedCrossRefGoogle Scholar
  77. 77.
    Fontana RJ, Hann HW, Wright T, et al. A multicenter study of lamivudine treatment in 33 patients with Hepatitis B after liver transplantation. Liver Transpl. 2001;6:504–10.CrossRefGoogle Scholar
  78. 78.
    Lai CL, Dienstag J, Schiff E, Leung NW, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687–96.PubMedCrossRefGoogle Scholar
  79. 79.
    Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology. 2001;120:1828–53.PubMedCrossRefGoogle Scholar
  80. 80.
    Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 1999;30:567–72.PubMedCrossRefGoogle Scholar
  81. 81.
    Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–17.PubMedCrossRefGoogle Scholar
  82. 82.
    Selcuk H, Karakayali H, Haberal M. Liver transplant and chronic hepatitis B virus infection. Exp Clin Transplant. 2011;9:94–7.PubMedGoogle Scholar
  83. 83.
    Neff GW, Nery J, Lau DTY, et al. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother. 2004;38:1999–2004.PubMedCrossRefGoogle Scholar
  84. 84.
    Jiménez-Pérez M, Saéz-Gómez AB, Mongil Ponce L, et al. Efficacy and safety of entecavir and/or tenofovir prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant Proc. 2010;42:3167–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Andres F. Carrion
    • 1
  • Paul Martin
    • 2
  • Christopher O’Brien
    • 2
  1. 1.University of Miami Miller School of Medicine, Miami Veterans Affairs Medical CenterMiamiUSA
  2. 2.University of Miami Miller School of MedicineMiamiUSA

Personalised recommendations